ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
ZD6474, a small molecule VEGFR and EGFR tyrosine kinase inhibitor, has been considered as a promising tumor-targeted drug in various malignancies. EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Impact Journals LLC
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673269/ |